Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
10.97
-0.27 (-2.40%)
At close: Nov 13, 2026, 4:00 PM EST
10.90
-0.07 (-0.64%)
After-hours: Nov 13, 2026, 7:30 PM EST
Gossamer Bio Revenue
Gossamer Bio had revenue of $38.43M in the quarter ending September 30, 2026, with 189.09% growth. This brings the company's total for the last twelve months to $78.42M, up 78.03% year-over-year. In the year 2025, Gossamer Bio had annual revenue of $48.47M, down -57.74%. That makes Gossamer Bio the 24,585th largest company in the world by revenue and 3,456th in the United States.
Revenue (ttm)
$78.42M
Revenue Growth
+78.03%
P/S Ratio
0.86
Revenue / Employee
$484,093
Employees
162
Market Cap
67.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.47M | -66.23M | -57.74% |
| Dec 31, 2024 | 114.70M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 68.47M |
| Champions Oncology | 60.66M |
| Rani Therapeutics Holdings | 6.58M |
| NeurAxis | 6.53M |
| Coya Therapeutics | 4.69M |
| MediciNova | 920.48K |
GOSS News
- 2 days ago - Gossamer Bio price target lowered to $96 from $120 at Piper Sandler - TheFly
- 3 days ago - Gossamer Bio reports Q3 EPS ($7.36), consensus ($3.93) - TheFly
- 3 days ago - Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 3 days ago - Gossamer Bio Quarterly report: Q3 2026 - Filings
- 3 days ago - Gossamer Bio Earnings release: Q3 2026 - Filings
- 4 weeks ago - Gossamer Bio initiated with a Buy at Chardan - TheFly
- 7 weeks ago - Gossamer Bio submits New Drug Application to FDA for seralutinib - TheFly
- 7 weeks ago - Gossamer Bio submits New Drug Application to FDA for seralutinib - TheFly